WLF Briefing Discusses FDA’s “Plaintiffs’ Bar Over Patients” Generic Drug Labeling Proposal

FDA’s Generic Drug Labeling Proposal: Unauthorized and Counterproductive Disturbance of the Hatch-Waxman Balance

Our Panelists

• Ralph G. Neas, The Generic Pharmaceutical Association
• Alex Brill, American Enterprise Institute
• Richard A. Samp, Washington Legal Foundation

Accompanying Materials

• WLF comments on FDA generic drug labeling proposal
• Proposed FDA generic drug regulation: Higher prices, no public health benefit (AEI article co-authored by Alex Brill)

• The FDA Should be in Charge of Warning Labels (Ralph Neas US News and World Report op-ed)